The increasing number of approved nucleic acid therapeutics demonstrates the potential to
treat diseases by targeting their genetic blueprints in vivo. Conventional treatments …

Nanoparticle-based RNA delivery has shown great progress in recent years with the
approval of two mRNA vaccines for Severe Acute Respiratory Syndrome Coronavirus 2 …

Ionizable cationic lipid-containing lipid nanoparticles (LNPs) are the most clinically
advanced non-viral gene delivery platforms, holding great potential for gene therapeutics …

CRISPR/Cas9 systems have great potential to achieve sophisticated gene therapy and cell
engineering by editing multiple genomic loci. However, to achieve efficient multiplex gene …

The complexity of CRISPR machinery is a challenge to its application for nonviral in vivo
therapeutic gene editing. Here, we demonstrate that proteins, regardless of size or charge …

The availability of analytical methods for the characterization of lipid nanoparticles (LNPs)
for in-vivo intracellular delivery of nucleic acids is critical for the fast development of …

The robust characterization of lipid nanoparticles (LNPs) encapsulating therapeutics or
vaccines is an important and multifaceted translational problem. Sedimentation velocity …

Lipid nanoparticles (LNPs) are effective vehicles to deliver mRNA vaccines and
therapeutics. It has been challenging to assess mRNA packaging characteristics in LNPs …

Particles in biopharmaceutical formulations remain a hot topic in drug product development.
With new product classes emerging it is crucial to discriminate particulate active …

Rational design and robust formulation processes are critical for optimal delivery of mRNA
by lipid nanoparticles (LNPs). Varying degrees of heterogeneity in mRNA-LNPs can affect …